Skip to content
Medical Health Aged Care

Psilocybin has treatment potential for a range of psychiatric conditions but remains poorly understood

The Florey 2 mins read

Medicinal psilocybin may prove to be an untapped therapeutic resource for a variety of psychiatric conditions identified by researchers at The Florey. 

In a paper published in the Journal of Neurochemistry, Florey researchers found that despite a recent “research explosion” into the naturally occurring psychoactive substance found in magic mushrooms, how it works remains poorly understood and needs to be subject of rigorous scientific research. 

Lead author James Gattuso said the team, led by Dr Thibault Renoir at The Florey, systematically reviewed 34 preclinical scientific papers published since 2000 to help shape the future direction of psilocybin research. 

"Psilocybin shows the greatest efficacy for mood disorders such as depression and anxiety. It also shows exciting therapeutic potential for obsessive compulsive disorder, addiction, and fear-related disorders such as post-traumatic stress disorder and phobias,” Mr Gattuso said. 

"Psilocybin has been found to be as safe if not safer than ketamine, which is FDA-approved for treatment-resistant depression. However, when taken recreationally, psilocybin is not only illegal but can carry significant health risks and concerns particularly for people with existing mental health conditions.” 

Mr Gattuso said future research should explore safe and long-term effects of psilocybin treatment. 

The review identified a variety of important future research directions, noting researchers could consider: 

  • Investigating how psilocybin affects the gut-brain axis which enables two-way biochemical signalling to take place between the gastrointestinal tract and the central nervous system and is known to be relevant to several neuropsychiatric conditions. 

  • Studying whether any benefits are due to psilocybin’s hallucinogenic properties or to other physiological factors. 

  • Working with genetically-engineered animal models as these allow researchers to understand the complex interaction between genes and environment and their impacts on behaviour. 

“We focused on preclinical psilocybin research because such studies can tightly control behavioural experiments, are less impacted by placebo effects and enable biochemical processes to be understood” Mr Gattuso said. 

The researchers also found that psilocybin can robustly increase the strength of synaptic connections while also altering the way key brain networks ‘talk’ to each other.  

Psilocybin was reclassified by the Therapeutic Goods Administration in Australia in July this year to allow prescription for patients with treatment-resistant depression, while the American Food and Drug Administration has classified it as a “breakthrough therapy”.  

The researchers concur that a limitation of the field is that the studies that were systematically reviewed contained large variability in study design such as the disease model, dosages used and behavioural tests applied. Therefore, much more research is needed to identify new treatments, including psilocybin and related drugs, for a variety of major psychiatric disorders. 

Read more about psilocybin research now underway at The Florey 


Contact details:

Media contact

Kath Powley, Manager, Media and Communications
kathryn.powley@florey.edu.au | +61 456 666 271

Media

More from this category

  • Medical Health Aged Care, Mental Health
  • 07/11/2024
  • 05:00
Black Dog Institute

Australian experts lead global push in Lancet Commission calls to tackle self-harm crisis

A landmark Lancet Commission report reveals cultural and societal issues are driving an increase in self-harm, underscoring the urgent need for governments to address this crisis. Over the last five years, a global team of more than 40 experts has brought together new perspectives on self-harm, bringing knowledge from those with lived experience, low- and middle-income countries (LMICs) and First Nations communities to better understand the drivers of self-harm and provide transformative ways forward. Launched in Australia today, the Commission paints a stark reality: 14 million episodes of self-harm are recorded globally every year, but this number is likely just…

  • Medical Health Aged Care
  • 06/11/2024
  • 13:41
Australian College of Nursing

ACN Transcript – Scope of Practice Review – ACN National Director Professional Practice Karen Grace

MEDIA TRANSCRIPT 6 November 2024 ACN National Director Professional Practice Karen GraceScope of Practice Review - 2CC Canberra Breakfast STEPHEN CENATIEMPO: This week, the final report of what's called the Unleashing the Potential of Our Health Workforce - Scope of Practice Review was released by the Health Minister Mark Butler, and look, it seems to be mixed reviews to it. The Australian College of General Practitioners say that some of the recommendations could make it harder to get people into a GP office, while the Australian College of Nursing has welcomed the findings and recommendations of this report. Karen Grace…

  • Medical Health Aged Care
  • 06/11/2024
  • 09:32
Australian Nursing and Midwifery Federation (ANMF).

Nurses and midwives helping deliver new models of healthcare

The recommendations of the ‘Unleashing the Potential of our Health Workforce’ Scope of Practice Review’ Final Report (‘Report’), allowing highly-trained nurses, midwives and allied health professionals to best utilise their skills, education and extensive experience, provides an important new framework for the delivery of integrated, quality healthcare services across the community, according to the Australian Nursing and Midwifery Federation (ANMF). The ANMF welcomed several of the key reforms for the health workforce, including allowing NPs, remote area nurses and endorsed midwives, to make direct referrals for a wider range of procedures and services with MBS rebates, without the need for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.